{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T20:31:02Z","timestamp":1787085062963,"version":"build-2736575974"},"reference-count":146,"publisher":"Begell House","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Immunol"],"published-print":{"date-parts":[[2026]]},"abstract":"<p>Chronic hepatitis B (CHB) infection leads to progressive dysfunction and exhaustion of antiviral immune cells, which is a primary obstacle to clinical cure. Although the phenotypic hallmarks of exhausted T cells are well described, the hierarchical trajectory, subset-specific heterogeneity, and underlying mechanisms of exhaustion across the full spectrum of immune cells in the unique hepatic microenvironment remain poorly defined. This review provides a comprehensive and critical synthesis of recent advances in immune exhaustion during CHB. We delineate the common and distinct exhaustion programs among T, B, and natural killer cells, highlighting the pivotal roles of transcription factors and metabolic dysregulation. Furthermore, we critically evaluate the limitations of current evidence and pinpoint critical knowledge gaps, such as the heterogeneity of non-classical exhausted subsets and the liver-resident immune compartment. By framing these findings within a critical and comparative context, this review not only updates our understanding of immune exhaustion but also proposes a roadmap for developing more precise immunotherapies aimed at achieving a functional cure for CHB.<\/p>","DOI":"10.1615\/critrevimmunol.2026061090","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:23:01Z","timestamp":1776108181000},"page":"23-44","source":"Crossref","is-referenced-by-count":0,"title":["Chronic Hepatitis B: Current Understanding and Clinical Implications of Immune Exhaustion"],"prefix":"10.1615","volume":"46","author":[{"given":"Yue","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546\u201355.","DOI":"10.1016\/S0140-6736(15)61412-X"},{"key":"2","unstructured":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383\u2013403."},{"key":"3","doi-asserted-by":"crossref","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthi eyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Le\u00f3n FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock M , Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095\u2013128.","DOI":"10.1016\/S0140-6736(12)61728-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Cui F, Blach S, Manzengo Mingiedi C, Gonzalez MA, Sabry Alaama A, Mozalevskis A, S\u00e9guy N, Rewari BB, Chan PL, Le LV, Doherty M, Luhmann N, Easterbrook P, Dirac M, de Martel C, Nayagam S, Hallett TB, Vickerman P, Razavi H, Lesi O, Low-Beer D. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023;8(4): 332\u201342.","DOI":"10.1016\/S2468-1253(22)00386-7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Hu JL, Huang AL. Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics. Virol Sin. 2024;39(1):9\u201323.","DOI":"10.1016\/j.virs.2023.12.005"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Suh DJ. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: Clinical outcomes and durability. Gut. 2014;63(8):1325\u201332.","DOI":"10.1136\/gutjnl-2013-305517"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Sonneveld MJ, Janssen HL. Chronic hepatitis B: Peginterferon or nucleos(t)ide analogues? Liver Int. 2011;31(Suppl 1):78\u201384.","DOI":"10.1111\/j.1478-3231.2010.02384.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M. Switching from entecavir to PegIFN alfa\u20132a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial). J Hepatol. 2014;61(4):777\u201384.","DOI":"10.1016\/j.jhep.2014.05.044"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Hu P, Shang J, Zhang WH, Gong GZ, Li YG, Chen XY, Jiang JN, Xie Q, Dou XG, Sun YT, Li YF, Liu YX, Liu GZ, Ma DW, Chi XL, Tang H, Li XO, Xie Y, Chen XP, Jiang JJ, Zha P, Hou JL, Gao ZL, Fan HM, Ding JG, Zhang DZ, Ren H. HBsAg loss with Pegylated-interferon alfa\u20132a in hepatitis B patients with partial response to nucleos(t)-ide analog: New switch study. Zhonghua Gan Zang Bing Za Zhi. 2018;26(10):756\u201364 (in Chinese).","DOI":"10.14218\/JCTH.2017.00072"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Huang D, Wu D, Wang P, Wang Y, Yuan W, Hu D, Hu J, Wang Y, Tao R, Xiao F, Zhang X, Wang X, Han M, Luo X, Yan W, Ning Q. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol. 2022;77(1):42\u201354.","DOI":"10.1016\/j.jhep.2022.01.021"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Wu D, Wang P, Han M, Chen Y, Chen X, Xia Q, Yan W, Wan X, Zhu C, Xie Q, Jiang J, Wei L, Tan D, Dou X, Yu Y, Hou J, Luo X, Ning Q. Sequential combination therapy with interferon, interleukin\u20132 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: The Endeavor study. Hepatol Int. 2019;13(5):573\u201386.","DOI":"10.1007\/s12072-019-09956-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Hansen BE, Schalm SW, Janssen HL. The safety of pegylated interferon alpha\u20132b in the treatment of chronic hepatitis B: Predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther. 2005;21(9):1163\u201371.","DOI":"10.1111\/j.1365-2036.2005.02453.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Feld JJ, Gehring AJ, Zoulim F. Getting to HBV Cure\u2013Will new biomarkers help? Hepatology. 2025:10\u201397.","DOI":"10.1097\/HEP.0000000000001334"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature. 1993;362(6422):758\u201361.","DOI":"10.1038\/362758a0"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Huang L, Ye B, Cao F, Ruan B, Li X. Single-cell atlas of the peripheral immune response in patients with chronic hepatitis B. J Med Virol. 2025;97(5):e70360.","DOI":"10.1002\/jmv.70360"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Huang X, Zhang W. Overcoming T cell exhaustion in tumor microenvironment via immune checkpoint modulation with nano-delivery systems for enhanced immunotherapy. Small Methods. 2024;8(8):e2301326.","DOI":"10.1002\/smtd.202301326"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Jia H, Yang H, Xiong H, Luo KQ. NK cell exhaustion in the tumor microenvironment. Front Immunol. 2023;14:1303605.","DOI":"10.3389\/fimmu.2023.1303605"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Lombardi A, Villa S, Castelli V, Bandera A, Gori A. T-cell exhaustion in mycobacterium tuberculosis and nontuberculous mycobacteria infection: Pathophysiology and therapeutic perspectives. Microorganisms. 2021;9(12):2460.","DOI":"10.3390\/microorganisms9122460"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Zhang Q, Liu X, Pang X, Wang H, Du J, Ren H, Hu P. Recovery of host adaptive immune function promoted the reduction of hepatitis B surface antigen in nucleoside analog-experienced chronic hepatitis B patients with low hepatitis B surface antigen levels. Cytokine. 2023;164:156140.","DOI":"10.1016\/j.cyto.2023.156140"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Kang SH, Cho DH, Choi J, Baik SK, Gwon JG, Kim MY. Association between chronic hepatitis B infection and COVID\u201319 outcomes: A Korean nationwide cohort study. PLoS One. 2021;16(10):e0258229.","DOI":"10.1371\/journal.pone.0258229"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5(3):215\u201329.","DOI":"10.1038\/nri1573"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003;77(1):68\u201376.","DOI":"10.1128\/JVI.77.1.68-76.2003"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell. 2009;138(1):30\u201350.","DOI":"10.1016\/j.cell.2009.06.036"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227\u201342.","DOI":"10.1038\/nri3405"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Raziorrouh B, Schraut W, Gerlach T, Nowack D, Gr\u00fcner NH, Ulsenheimer A, Zachoval R, W\u00e4chtler M, Spannagl M, Haas J, Diepolder HM, Jung MC. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology. 2010;52(6):1934\u201347.","DOI":"10.1002\/hep.23936"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J Gen Virol. 2006;87(Pt 6):1439\u201349.","DOI":"10.1099\/vir.0.81920-0"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492\u20139.","DOI":"10.1038\/ni.2035"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10(1):29\u201337.","DOI":"10.1038\/ni.1679"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Hakim MS, Rahmadika N, Jariah ROA. Expressions of inhibitory checkpoint molecules in acute and chronic HBV and HCV infections: Implications for therapeutic monitoring and personalized therapy. Rev Med Virol. 2020;30(2):e2094.","DOI":"10.1002\/rmv.2094"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Zhang Z, Zhang JY, Wherry EJ, Jin B, Xu B, Zou ZS, Zhang SY, Li BS, Wang HF, Wu H, Lau GK, Fu YX, Wang FS. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology. 2008;134(7):1938\u201349, 49.e1\u20133.","DOI":"10.1053\/j.gastro.2008.03.037"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol. 2008;45(4):963\u201370.","DOI":"10.1016\/j.molimm.2007.07.038"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Li CZ, Hu JJ, Xue JY, Yin W, Liu YY, Fan WH, Xu H, Liang XS. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B. World J Gastroenterol. 2014;20(28):9486\u201396.","DOI":"10.3748\/wjg.v20.i28.9486"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Huyen PTM, Dung DTN, Wei\u00df PJ, Hoan PQ, Giang DP, Uyen NT, Van Tuan N, Trung NT, Velavan TP, Song LH, Hoan NX. Circulating level of sPD-1 and PD-1 genetic variants are associated with hepatitis B infection and related liver disease progression. Int J Infect Dis. 2022;115:229\u201336.","DOI":"10.1016\/j.ijid.2021.12.325"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Hu HH, Jeng WJ, Pan MH, Luo WS, Chang CL, Huang YT, Su CY, Chiang CT, Jen CL, Chien YC, Lu SN, Wang LY, Huang LR, Lee MH, Liu J, Nguyen MH, Chen CJ, Yang HI. Serum soluble programmed cell death 1 levels predict spontaneous functional cure in inactive carriers with chronic hepatitis B. Aliment Pharmacol Ther. 2022;55(5):558\u201367.","DOI":"10.1111\/apt.16752"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Cai G, Nie X, Li L, Hu L, Wu B, Lin J, Jiang C, Wang H, Wang X, Shen Q. B and T lymphocyte attenuator is highly expressed on intrahepatic T cells during chronic HBV infection and regulates their function. J Gastroenterol. 2013;48(12):1362\u201372.","DOI":"10.1007\/s00535-013-0762-9"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Wang H, Wu B, Li L, Hu L, Lin J, Jiang C, Cai G, Shen Q. Hepatic expansion of virus-specific CD8(+)BTLA(+) T cells with regulatory properties in chronic hepatitis B virus infection. Cell Immunol. 2017;311:36\u201345.","DOI":"10.1016\/j.cellimm.2016.10.002"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Liu S, Xu C, Yang F, Zong L, Qin Y, Gao Y, Su Q, Li T, Li Y, Xu Y, Zheng M. Natural killer cells induce CD8(+) T cell dysfunction via galectin\u20139\/TIM\u20133 in chronic hepatitis B virus infection. Front Immunol. 2022;13:884290.","DOI":"10.3389\/fimmu.2022.884290"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Xie H, Deng H, Yang X, Gao X, Yang S, Chen W, Wang Y, Yang N, Yong L, Hou X. Mesencephalic astrocyte-derived neurotrophic factor supports hepatitis B virus-induced immunotolerance. Cell Mol Gastroenterol Hepatol. 2024;18(3):101360.","DOI":"10.1016\/j.jcmgh.2024.05.008"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Huang A, Zhang B, Yan W, Wang B, Wei H, Zhang F, Wu L, Fan K, Guo Y. Myeloid-derived suppressor cells regulate immune response in patients with chronic hepatitis B virus infection through PD-1-induced IL-10. J Immunol. 2014;193(11):5461\u20139.","DOI":"10.4049\/jimmunol.1400849"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Trehanpati N, Vyas AK. Immune regulation by T regulatory cells in hepatitis B virus-related inflammation and cancer. Scand J Immunol. 2017;85(3):175\u201381.","DOI":"10.1111\/sji.12524"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Liu Y, Luo Y, Zhu T, Jiang M, Tian Z, Tang G, Liang X. Regulatory B cells dysregulated T cell function in an IL-35-dependent way in patients with chronic hepatitis B. Front Immunol. 2021;12:653198.","DOI":"10.3389\/fimmu.2021.653198"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Utzschneider DT, Charmoy M, Chennupati V, Pousse L, Ferreira DP, Calderon-Copete S, Danilo M, Alfei F, Hofmann M, Wieland D, Pradervand S, Thimme R, Zehn D, Held W. T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity. 2016;45(2):415\u201327.","DOI":"10.1016\/j.immuni.2016.07.021"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Johnson JL, Georgakilas G, Petrovic J, Kurachi M, Cai S, Harly C, Pear WS, Bhandoola A, Wherry EJ, Vahedi G. Lineage-determining transcription factor TCF\u20131 initiates the epigenetic identity of T cells. Immunity. 2018;48(2):243\u201357.e10.","DOI":"10.1016\/j.immuni.2018.01.012"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Jadhav RR, Im SJ, Hu B, Hashimoto M, Li P, Lin JX, Leonard WJ, Greenleaf WJ, Ahmed R, Goronzy JJ. Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade. Proc Natl Acad Sci U S A. 2019;116(28):14113\u20138.","DOI":"10.1073\/pnas.1903520116"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Zhou W, Qu M, Yue Y, Zhong Z, Nan K, Sun X, Wu Q, Zhang J, Chen W, Miao C. Acetylcysteine synergizes PD-1 blockers against colorectal cancer progression by promoting TCF1(+)PD1(+)CD8(+) T cell differentiation. Cell Commun Signal. 2024;22(1):503.","DOI":"10.1186\/s12964-024-01848-8"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Chen Z, Ji Z, Ngiow SF, Manne S, Cai Z, Huang AC, Johnson J, Staupe RP, Bengsch B, Xu C, Yu S, Kurachi M, Herati RS, Vella LA, Baxter AE, Wu JE, Khan O, Beltra JC, Giles JR, Stelekati E, McLane LM, Lau CW, Yang X, Berger SL, Vahedi G, Ji H, Wherry EJ. TCF\u20131-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision. Immunity. 2019;51(5):840\u201355.e5.","DOI":"10.1016\/j.immuni.2019.09.013"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Zhu Y, Ju S, Chen E, Dai S, Li C, Morel P, Liu L, Zhang X, Lu B. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. J Immunol. 2010;185(6):3174\u201383.","DOI":"10.4049\/jimmunol.1000749"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Lazarevic V, Glimcher LH. T-bet in disease. Nat Immunol. 2011;12(7):597\u2013606.","DOI":"10.1038\/ni.2059"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Fan R, Lan Y, Chen J, Huang Y, Yan Q, Jiang L, Song S, Li Y. T-bet expression in CD8+ T cells associated with chronic hepatitis B virus infection. Virol J. 2016;13:14.","DOI":"10.1186\/s12985-016-0473-y"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE, Bikoff EK, Robertson EJ, Lauer GM, Reiner SL, Wherry EJ. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science. 2012;338(6111):1220\u20135.","DOI":"10.1126\/science.1229620"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, Werner MT, Huang AC, Alexander KA, Wu JE, Attanasio J, Yan P, George SM, Bengsch B, Staupe RP, Donahue G, Xu W, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Schuchter LM, Kaye J, Berger SL, Wherry EJ. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature. 2019;571(7764):211\u20138.","DOI":"10.1038\/s41586-019-1325-x"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Sen DR, Kaminski J, Barnitz RA, Kurachi M, Gerdemann U, Yates KB, Tsao HW, Godec J, LaFleur MW, Brown FD, Tonnerre P, Chung RT, Tully DC, Allen TM, Frahm N, Lauer GM, Wherry EJ, Yosef N, Haining WN. The epigenetic landscape of T cell exhaustion. Science. 2016;354(6316):1165\u20139.","DOI":"10.1126\/science.aae0491"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Heim K, Binder B, Sagar, Wieland D, Hensel N, Llewellyn-Lacey S, Gostick E, Price DA, Emmerich F, Vingerhoet H, Kraft ARM, Cornberg M, Boettler T, Neumann-Haefelin C, Zehn D, Bengsch B, Hofmann M, Thimme R. TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection. Gut. 2020;70(8):1550\u201360.","DOI":"10.1136\/gutjnl-2020-322404"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Thimme R, Bertoletti A, Iannacone M. Beyond exhaustion: The unique characteristics of CD8(+) T cell dysfunction in chronic HBV infection. Nat Rev Immunol. 2024;24(11):775\u20136.","DOI":"10.1038\/s41577-024-01097-3"},{"key":"55","doi-asserted-by":"crossref","unstructured":"B\u00e9n\u00e9chet AP, De Simone G, Di Lucia P, Cilenti F, Barbiera G, Le Bert N, Fumagalli V, Lusito E, Moalli F, Bianchessi V, Andreata F, Zordan P, Bono E, Giustini L, Bonilla WV, Bleriot C, Kunasegaran K, Gonzalez-Aseguinolaza G, Pinschewer DD, Kennedy PTF, Naldini L, Kuka M, Ginhoux F, Cantore A, Bertoletti A, Ostuni R, Guidotti LG, Iannacone M. Dynamics and genomic landscape of CD8(+) T cells undergoing hepatic priming. Nature. 2019;574(7777):200\u20135.","DOI":"10.1038\/s41586-019-1620-6"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Allahmoradi E, Mohammadi R, Kheirandish Zarandi P, Alavian SM, Heiat M. The CD8+ T cell exhaustion mechanisms in chronic hepatitis B infection and immunotherapeutic strategies: A systematic review. Expert Rev Clin Immunol. 2023;19(6):671\u201388.","DOI":"10.1080\/1744666X.2023.2198209"},{"key":"57","doi-asserted-by":"crossref","unstructured":"Bosch M, Kallin N, Donakonda S, Zhang JD, Wintersteller H, Hegenbarth S, Heim K, Ramirez C, F\u00fcrst A, Lattouf EI, Feuerherd M, Chattopadhyay S, Kumpesa N, Griesser V, Hoflack JC, Siebourg-Polster J, Mogler C, Swadling L, Pallett LJ, Meiser P, Manske K, de Almeida GP, Kosinska AD, Sandu I, Schneider A, Steinbacher V, Teng Y, Schnabel J, Theis F, Gehring AJ, Boonstra A, Janssen HLA, Vandenbosch M, Cuypers E, \u00d6llinger R, Engleitner T, Rad R, Steiger K, Oxenius A, Lo WL, Klepsch V, Baier G, Holzmann B, Maini MK, Heeren R, Murray PJ, Thimme R, Herrmann C, Protzer U, B\u00f6ttcher JP, Zehn D, Wohlleber D, Lauer GM, Hofmann M, Luangsay S, Knolle PA. A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection. Nature. 2024;631(8022):867\u201375.","DOI":"10.1038\/s41586-024-07630-7"},{"key":"58","doi-asserted-by":"crossref","unstructured":"Schuch A, Salimi Alizei E, Heim K, Wieland D, Kiraithe MM, Kemming J, Llewellyn-Lacey S, Sogukpinar \u00d6, Ni Y, Urban S, Zimmermann P, Nassal M, Emmerich F, Price DA, Bengsch B, Luxenburger H, Neumann-Haefelin C, Hofmann M, Thimme R. Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load. Gut. 2019;68(5):905\u201315.","DOI":"10.1136\/gutjnl-2018-316641"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Zander R, Schauder D, Xin G, Nguyen C, Wu X, Zajac A, Cui W. CD4(+) T cell help is required for the formation of a cytolytic CD8(+) T cell subset that protects against chronic infection and cancer. Immunity. 2019;51(6):1028\u201342.e4.","DOI":"10.1016\/j.immuni.2019.10.009"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Hoogeveen RC, Dijkstra S, Bartsch LM, Drescher HK, Aneja J, Robidoux MP, Cheney JA, Timm J, Gehring A, de Sousa PSF, Ximenez L, Peliganga LB, Pitts A, Evans FB, Boonstra A, Kim AY, Lewis-Ximenez LL, Lauer GM. Hepatitis B virus-specific CD4 T cell responses differentiate functional cure from chronic surface antigen(+) infection. J Hepatol. 2022;77(5):1276\u201386.","DOI":"10.1016\/j.jhep.2022.05.041"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Dong Y, Li X, Zhang L, Zhu Q, Chen C, Bao J, Chen Y. CD4(+) T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B. BMC Immunol. 2019;20(1):27.","DOI":"10.1186\/s12865-019-0309-9"},{"key":"62","doi-asserted-by":"crossref","unstructured":"Zhang X, Wang X, Wu M, Ghildyal R, Yuan Z. Animal models for the study of hepatitis B virus pathobiology and immunity: Past, present, and future. Front Microbiol. 2021;12:715450.","DOI":"10.3389\/fmicb.2021.715450"},{"key":"63","doi-asserted-by":"crossref","unstructured":"Kuo MH, Tseng CW, Lee CH, Tung CH, Tseng KC, Lai NS. Moderate risk of hepatitis B virus reactivation in HBsAg(-)\/HBcAb(+) carriers receiving rituximab for rheumatoid arthritis. Sci Rep. 2020;10(1):2456.","DOI":"10.1038\/s41598-020-59406-4"},{"key":"64","doi-asserted-by":"crossref","unstructured":"Chen YM, Chen HH, Huang WN, Chen YH, Hsieh TY, Yang SS, Lan JL, Chen DY. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation. Int J Rheum Dis. 2019;22(6):1145\u201351.","DOI":"10.1111\/1756-185X.13582"},{"key":"65","doi-asserted-by":"crossref","unstructured":"Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019;133(2):137\u201346.","DOI":"10.1182\/blood-2018-04-848044"},{"key":"66","doi-asserted-by":"crossref","unstructured":"Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27(4):605\u201311.","DOI":"10.1200\/JCO.2008.18.0182"},{"key":"67","doi-asserted-by":"crossref","unstructured":"Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, Alberts E, Davidson BR, Kennedy PT, Gill US, Mauri C, Blair PA, Pelletier N, Maini MK. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest. 2018;128(10):4588\u2013603.","DOI":"10.1172\/JCI121960"},{"key":"68","doi-asserted-by":"crossref","unstructured":"Vanwolleghem T, Groothuismink ZMA, Kreefft K, Hung M, Novikov N, Boonstra A. Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV. J Hepatol. 2020;73(1):52\u201361.","DOI":"10.1016\/j.jhep.2020.01.024"},{"key":"69","doi-asserted-by":"crossref","unstructured":"Le Bert N, Salimzadeh L, Gill US, Dutertre CA, Facchetti F, Tan A, Hung M, Novikov N, Lampertico P, Fletcher SP, Kennedy PTF, Bertoletti A. Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B. J Hepatol. 2020;72(1):34\u201344.","DOI":"10.1016\/j.jhep.2019.07.015"},{"key":"70","doi-asserted-by":"crossref","unstructured":"Vanlandschoot P, Cao T, Leroux-Roels G. The nucleocapsid of the hepatitis B virus: A remarkable immunogenic structure. Antiviral Res. 2003;60(2):67\u201374.","DOI":"10.1016\/j.antiviral.2003.08.011"},{"key":"71","doi-asserted-by":"crossref","unstructured":"Fisicaro P, Barili V, Rossi M, Montali I, Vecchi A, Acerbi G, Laccabue D, Zecca A, Penna A, Missale G, Ferrari C, Boni C. Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches. Front Immunol. 2020;11:849.","DOI":"10.3389\/fimmu.2020.00849"},{"key":"72","doi-asserted-by":"crossref","unstructured":"Van Hees S, Cuypers B, Bourgeois S, Groothuismink ZMA, Meysman P, Van der Vlies P, de Knegt R, Vonghia L, Michielsen P, Francque S, Laukens K, Boonstra A, Vanwolleghem T. Sorted B cell transcriptomes point towards actively regulated B cell responses during ongoing chronic hepatitis B infections. Cell Immunol. 2021;362:104283.","DOI":"10.1016\/j.cellimm.2021.104283"},{"key":"73","doi-asserted-by":"crossref","unstructured":"Osmani Z, Boonstra A. Recent insights into the role of B cells in chronic hepatitis B and C infections. Pathogens. 2023;12(6):815.","DOI":"10.3390\/pathogens12060815"},{"key":"74","doi-asserted-by":"crossref","unstructured":"Li J, Chen S, Zhen C, Fan P, Tang L, Zhang Y, Wang FS, Zhang C. Single-cell transcriptomic profiling reveals dysregulation of B-cell subset function in patients with chronic hepatitis B. Hepatol Int. 2025;19(4):760\u201372.","DOI":"10.1007\/s12072-025-10846-y"},{"key":"75","doi-asserted-by":"crossref","unstructured":"Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1(5):405\u201313.","DOI":"10.1016\/1074-7613(94)90071-X"},{"key":"76","doi-asserted-by":"crossref","unstructured":"Sage PT, Paterson AM, Lovitch SB, Sharpe AH. The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity. 2014;41(6):1026\u201339.","DOI":"10.1016\/j.immuni.2014.12.005"},{"key":"77","doi-asserted-by":"crossref","unstructured":"Wing JB, Ise W, Kurosaki T, Sakaguchi S. Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity. 2014;41(6):1013\u201325.","DOI":"10.1016\/j.immuni.2014.12.006"},{"key":"78","doi-asserted-by":"crossref","unstructured":"Yin S, Mao M, Gong L, Zhu Y, Wan Y, Tong X, Wang J, Wang G, Liu Y, Wu C, Huang R, Chen Y. CTLA4 modulates B cell receptor signals to inhibit HBsAb secretion in chronic hepatitis B patients. Biochim Biophys Acta Mol Basis Dis. 2025;1871(6):167848.","DOI":"10.1016\/j.bbadis.2025.167848"},{"key":"79","doi-asserted-by":"crossref","unstructured":"Yin S, Wang J, Chen L, Mao M, Issa R, Geng Y, Huang R, Tong X, Liu Y, Wu C, Chen Y, Li J. Circulating Th2-biased T follicular helper cells impede antiviral humoral responses during chronic hepatitis B infection through upregulating CTLA4. Antiviral Res. 2023;216:105665.","DOI":"10.1016\/j.antiviral.2023.105665"},{"key":"80","doi-asserted-by":"crossref","unstructured":"Marcenaro E, Carlomagno S, Pesce S, Moretta A, Sivori S. Bridging innate NK cell functions with adaptive immunity. Adv Exp Med Biol. 2011;780:45\u201355.","DOI":"10.1007\/978-1-4419-5632-3_5"},{"key":"81","doi-asserted-by":"crossref","unstructured":"Ju Y, Hou N, Meng J, Wang X, Zhang X, Zhao D, Liu Y, Zhu F, Zhang L, Sun W, Liang X, Gao L, Ma C. T cell immunoglobulin-and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol. 2010;52(3):322\u20139.","DOI":"10.1016\/j.jhep.2009.12.005"},{"key":"82","doi-asserted-by":"crossref","unstructured":"Wang J, Hou H, Mao L, Wang F, Yu J, Luo Y, Lin Q, Sun Z. TIGIT signaling pathway regulates natural killer cell function in chronic hepatitis B virus infection. Front Med. 2021;8:816474.","DOI":"10.3389\/fmed.2021.816474"},{"key":"83","doi-asserted-by":"crossref","unstructured":"Ma Q, Dong X, Liu S, Zhong T, Sun D, Zong L, Zhao C, Lu Q, Zhang M, Gao Y, Ye Y, Cheng J, Xu Y, Zheng M. Hepatitis B e antigen induces NKG2A(+) natural killer cell dysfunction via regulatory T cell-derived interleukin 10 in chronic hepatitis B virus infection. Front Cell Dev Biol. 2020;8:421.","DOI":"10.3389\/fcell.2020.00421"},{"key":"84","doi-asserted-by":"crossref","unstructured":"Sun C, Xu J, Huang Q, Huang M, Wen H, Zhang C, Wang J, Song J, Zheng M, Sun H, Wei H, Xiao W, Sun R, Tian Z. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. Oncoimmunology. 2017;6(1):e1264562.","DOI":"10.1080\/2162402X.2016.1264562"},{"key":"85","doi-asserted-by":"crossref","unstructured":"Li F, Wei H, Wei H, Gao Y, Xu L, Yin W, Sun R, Tian Z. Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice. Gastroenterology. 2013;144(2):392\u2013401.","DOI":"10.1053\/j.gastro.2012.10.039"},{"key":"86","doi-asserted-by":"crossref","unstructured":"Zhang Y, Tong S, Li S, Wang X, Ren H, Yin W. Increased ILT2 expression contributes to dysfunction of CD56(dim) CD16(+)NK cells in chronic hepatitis B virus infection. Antiviral Res. 2022;205:105385.","DOI":"10.1016\/j.antiviral.2022.105385"},{"key":"87","unstructured":"Li MH, Zhang QF, Yin WW, Zhang DZ, Ren H. Functional effects of killer cell lectin-like receptor subfamily G member 1 on natural killer cells in chronic hepatitis B infection. Zhonghua Gan Zang Bing Za Zhi. 2018;26(8):585\u20139 (in Chinese)."},{"key":"88","doi-asserted-by":"crossref","unstructured":"De Pasquale C, Campana S, Barberi C, Sidoti Migliore G, Oliveri D, Lanza M, Musolino C, Raimondo G, Ferrone S, Pollicino T, Ferlazzo G. Human hepatitis B virus negatively impacts the protective immune crosstalk between natural killer and dendritic cells. Hepatology. 2021;74(2):550\u201365.","DOI":"10.1002\/hep.31725"},{"key":"89","doi-asserted-by":"crossref","unstructured":"Du Y, Anastasiou OE, Strunz B, Scheuten J, Bremer B, Kraft A, Kleinsimglinhaus K, Todt D, Broering R, Hardtke-Wolenski M, Wu J, Yang D, Dittmer U, Lu M, Cornberg M, Bj\u00f6rkstr\u00f6m NK, Khera T, Wedemeyer H. The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection. Liver Int. 2021;41(9):2046\u201358.","DOI":"10.1111\/liv.14885"},{"key":"90","doi-asserted-by":"crossref","unstructured":"Marotel M, Villard M, Drouillard A, Tout I, Besson L, Allatif O, Pujol M, Rocca Y, Ainouze M, Roblot G, Viel S, Gomez M, Loustaud V, Alain S, Durantel D, Walzer T, Hasan U, Mar\u00e7ais A. Peripheral natural killer cells in chronic hepatitis B patients display multiple molecular features of T cell exhaustion. Elife. 2021;10:e60095.","DOI":"10.7554\/eLife.60095"},{"key":"91","doi-asserted-by":"crossref","unstructured":"Yang Y, Han Q, Zhang C, Xiao M, Zhang J. Hepatitis B virus antigens impair NK cell function. Int Immunopharmacol. 2016;38:291\u20137.","DOI":"10.1016\/j.intimp.2016.06.015"},{"key":"92","doi-asserted-by":"crossref","unstructured":"Yang Y, Han Q, Hou Z, Zhang C, Tian Z, Zhang J. Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction. Cell Mol Immunol. 2017;14(5):465\u201375.","DOI":"10.1038\/cmi.2016.24"},{"key":"93","doi-asserted-by":"crossref","unstructured":"Huang X, Mo Q, Fu T, Liu Y, Diao B. STAT1 is associated with NK cell dysfunction by downregulating NKG2D transcription in chronic HBV-infected patients. Immunobiology. 2022;227(6):152272.","DOI":"10.1016\/j.imbio.2022.152272"},{"key":"94","doi-asserted-by":"crossref","unstructured":"Zheng B, Yang Y, Han Q, Yin C, Pan Z, Zhang J. STAT3 directly regulates NKp46 transcription in NK cells of HBeAg-negative CHB patients. J Leukoc Biol. 2019;106(4):987\u201396.","DOI":"10.1002\/JLB.2A1118-421R"},{"key":"95","doi-asserted-by":"crossref","unstructured":"Zheng B, Yu Y, Pan Z, Feng Y, Zhao H, Han Q, Zhang J. HBsAg dampened STING associated activation of NK cells in HBeAg-negative CHB patients. Int J Mol Sci. 2021;22(14):7643.","DOI":"10.3390\/ijms22147643"},{"key":"96","doi-asserted-by":"crossref","unstructured":"Schupp AK, Trilling M, Rattay S, Le-Trilling VTK, Haselow K, Stindt J, Zimmermann A, H\u00e4ussinger D, Hengel H, Graf D. Bile acids act as soluble host restriction factors limiting cytomegalovirus replication in hepatocytes. J Virol. 2016;90(15):6686\u201398.","DOI":"10.1128\/JVI.00299-16"},{"key":"97","doi-asserted-by":"crossref","unstructured":"Song X, Sun X, Oh SF, Wu M, Zhang Y, Zheng W, Geva-Zatorsky N, Jupp R, Mathis D, Benoist C, Kasper DL. Microbial bile acid metabolites modulate gut ROR\u03b3(+) regulatory T cell homeostasis. Nature. 2020;577(7790):410\u20135.","DOI":"10.1038\/s41586-019-1865-0"},{"key":"98","doi-asserted-by":"crossref","unstructured":"Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, Agdashian D, Terabe M, Berzofsky JA, Fako V, Ritz T, Longerich T, Theriot CM, McCulloch JA, Roy S, Yuan W, Thovarai V, Sen SK, Ruchirawat M, Korangy F, Wang XW, Trinchieri G, Greten TF. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018;360(6391):eaan5931.","DOI":"10.1126\/science.aan5931"},{"key":"99","doi-asserted-by":"crossref","unstructured":"Xun Z, Lin J, Yu Q, Liu C, Huang J, Shang H, Guo J, Ye Y, Wu W, Zeng Y, Wu S, Xu S, Chen T, Chen J, Ou Q. Taurocholic acid inhibits the response to interferon-\u03b1 therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8(+) T and NK cell function. Cell Mol Immunol. 2021;18(2):461\u201371.","DOI":"10.1038\/s41423-020-00601-8"},{"key":"100","doi-asserted-by":"crossref","unstructured":"Crispe IN. Liver antigen-presenting cells. J Hepatol. 2011;54(2):357\u201365.","DOI":"10.1016\/j.jhep.2010.10.005"},{"key":"101","doi-asserted-by":"crossref","unstructured":"Yonejima A, Mizukoshi E, Tamai T, Nakagawa H, Kitahara M, Yamashita T, Arai K, Terashima T, Iida N, Fushimi K, Okada H, Yamashita T, Sakai Y, Honda M, Kaneko S. Characteristics of impaired dendritic cell function in patients with hepatitis B virus infection. Hepatology. 2019;70(1):25\u201339.","DOI":"10.1002\/hep.30637"},{"key":"102","doi-asserted-by":"crossref","unstructured":"Golsaz-Shirazi F, Amiri MM, Shokri F. Immune function of plasmacytoid dendritic cells, natural killer cells, and their crosstalk in HBV infection. Rev Med Virol. 2018;28(6):e2007.","DOI":"10.1002\/rmv.2007"},{"key":"103","doi-asserted-by":"crossref","unstructured":"Singh AK, Rooge SB, Varshney A, Vasudevan M, Kumar M, Geffers R, Kumar V, Sarin SK. Identification of miRNAs associated with dendritic cell dysfunction during acute and chronic hepatitis B virus infection. J Med Virol. 2021;93(6):3697\u2013706.","DOI":"10.1002\/jmv.26629"},{"key":"104","doi-asserted-by":"crossref","unstructured":"Li M, Zhou ZH, Sun XH, Zhang X, Zhu XJ, Jin SG, Gao YT, Jiang Y, Gao YQ. Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT\/ERK\/P38 pathway: A possible mechanism of hepatitis B virus persistence. Lab Invest. 2016;96(11):1156\u201364.","DOI":"10.1038\/labinvest.2016.96"},{"key":"105","doi-asserted-by":"crossref","unstructured":"Zhao H, Yu Y, Wang Y, Zhao L, Yang A, Hu Y, Pan Z, Wang Z, Yang J, Han Q, Tian Z, Zhang J. Cholesterol accumulation on dendritic cells reverses chronic hepatitis B virus infection-induced dysfunction. Cell Mol Immunol. 2022;19(12):1347\u201360.","DOI":"10.1038\/s41423-022-00939-1"},{"key":"106","doi-asserted-by":"crossref","unstructured":"Shu Y, Li S, Du Y, Zheng X. Anti-HBV treatment partially restores the dysfunction of innate immune cells and unconventional T cells during chronic HBV infection. Front Immunol. 2025;16:1611976.","DOI":"10.3389\/fimmu.2025.1611976"},{"key":"107","doi-asserted-by":"crossref","unstructured":"Wang C, Zai W, Zhao K, Li Y, Shi B, Wu M, Zhou X, Kozlowski M, Zhang X, Fang Z, Yuan Z. Potential role of liver-resident CD3(+) macrophages in HBV clearance in a mouse hepatitis B model. JHEP Rep. 2025;7(4):101323.","DOI":"10.1016\/j.jhepr.2024.101323"},{"key":"108","doi-asserted-by":"crossref","unstructured":"Faure-Dupuy S, Delphin M, Aillot L, Dimier L, Leboss\u00e9 F, Fresquet J, Parent R, Matter MS, Rivoire M, Bendriss-Vermare N, Salvetti A, Heide D, Flores L, Klumpp K, Lam A, Zoulim F, Heikenw\u00e4lder M, Durantel D, Lucifora J. Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection. J Hepatol. 2019;71(6):1086\u201398.","DOI":"10.1016\/j.jhep.2019.06.032"},{"key":"109","doi-asserted-by":"crossref","unstructured":"Wu L, Deng H, Feng X, Xie D, Li Z, Chen J, Mo Z, Zhao Q, Hu Z, Yi S, Meng S, Wang J, Li X, Lin B, Gao Z. Interferon-\u03b3(+) Th1 activates intrahepatic resident memory T cells to promote HBsAg loss by inducing M1 macrophage polarization. J Med Virol. 2024;96(5):e29627.","DOI":"10.1002\/jmv.29627"},{"key":"110","doi-asserted-by":"crossref","unstructured":"Ilan Y, Nagler A, Adler R, Naparstek E, Or R, Slavin S, Brautbar C, Shouval D. Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology. 1993;18(2):246\u201352.","DOI":"10.1002\/hep.1840180204"},{"key":"111","doi-asserted-by":"crossref","unstructured":"Kah J, Koh S, Volz T, Ceccarello E, Allweiss L, L\u00fctgehetmann M, Bertoletti A, Dandri M. Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection. J Clin Invest. 2017;127(8):3177\u201388.","DOI":"10.1172\/JCI93024"},{"key":"112","doi-asserted-by":"crossref","unstructured":"Koh S, Kah J, Tham CYL, Yang N, Ceccarello E, Chia A, Chen M, Khakpoor A, Pavesi A, Tan AT, Dandri M, Bertoletti A. Nonlytic lymphocytes engineered to express virus-specific T-cell receptors limit HBV infection by activating APOBEC3. Gastroenterology. 2018;155(1):180\u201393.e6.","DOI":"10.1053\/j.gastro.2018.03.027"},{"key":"113","doi-asserted-by":"crossref","unstructured":"Wisskirchen K, Kah J, Malo A, Asen T, Volz T, Allweiss L, Wettengel JM, L\u00fctgehetmann M, Urban S, Bauer T, Dandri M, Protzer U. T cell receptor grafting allows virological control of Hepatitis B virus infection. J Clin Invest. 2019;129(7):2932\u201345.","DOI":"10.1172\/JCI120228"},{"key":"114","doi-asserted-by":"crossref","unstructured":"Krebs K, B\u00f6ttinger N, Huang LR, Chmielewski M, Arzberger S, Gasteiger G, J\u00e4ger C, Schmitt E, Bohne F, Aichler M, Uckert W, Abken H, Heikenwalder M, Knolle P, Protzer U. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology. 2013;145(2):456\u201365.","DOI":"10.1053\/j.gastro.2013.04.047"},{"key":"115","doi-asserted-by":"crossref","unstructured":"Kruse RL, Shum T, Tashiro H, Barzi M, Yi Z, Whitten-Bauer C, Legras X, Bissig-Choisat B, Garaigorta U, Gottschalk S, Bissig KD. HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. Cytotherapy. 2018;20(5):697\u2013705.","DOI":"10.1016\/j.jcyt.2018.02.002"},{"key":"116","doi-asserted-by":"crossref","unstructured":"Zhang Y, Bourgine M, Wan Y, Song J, Li Z, Yu Y, Jiang W, Zhou M, Guo C, Santucci D, Liang X, Brechot C, Zhang W, Charneau P, Wu H, Qiu C. Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers. J Hepatol. 2024;80(1):31\u201340.","DOI":"10.1016\/j.jhep.2023.09.019"},{"key":"117","doi-asserted-by":"crossref","unstructured":"Bunse T, Kosinska AD, Michler T, Protzer U. PD-L1 silencing in liver using siRNAs enhances efficacy of therapeutic vaccination for chronic hepatitis B. Biomolecules. 2022;12(3):470.","DOI":"10.3390\/biom12030470"},{"key":"118","doi-asserted-by":"crossref","unstructured":"Zhao H, Han Q, Yang A, Wang Y, Wang G, Lin A, Wang X, Yin C, Zhang J. CpG-C ODN M362 as an immunoadjuvant for HBV therapeutic vaccine reverses the systemic tolerance against HBV. Int J Biol Sci. 2022;18(1):154\u201365.","DOI":"10.7150\/ijbs.62424"},{"key":"119","doi-asserted-by":"crossref","unstructured":"Jiang P, Jia H, Qian X, Tang T, Han Y, Zhang Z, Jiang L, Yu Z, Zheng L, Yu G, Cai H, Zhang S, Zhang X, Gu J, Ye C, Yang L, Lu Y, Liu H, Lu X, Jin C, Ren Y, Lu M, Xu L, Yu J, Jin X, Yang Y, Qian P. Single-cell RNA sequencing reveals the immunoregulatory roles of PegIFN-\u03b1 in patients with chronic hepatitis B. Hepatology. 2024;79(1):167\u201382.","DOI":"10.1097\/HEP.0000000000000524"},{"key":"120","doi-asserted-by":"crossref","unstructured":"Zhu L, Li J, Xu J, Chen F, Wu X, Zhu C. Significance of T-cell subsets for clinical response to peginterferon alfa\u20132a therapy in HBeAg-positive chronic hepatitis B patients. Int J Gen Med. 2022;15:4441\u201351.","DOI":"10.2147\/IJGM.S356696"},{"key":"121","doi-asserted-by":"crossref","unstructured":"Wang D, Fu B, Shen X, Guo C, Liu Y, Zhang J, Sun R, Ye Y, Li J, Tian Z, Wei H. Restoration of HBV-specific CD8(+) T-cell responses by sequential low-dose IL\u20132 treatment in non-responder patients after IFN-\u03b1 therapy. Signal Transduct Target Ther. 2021;6(1):376.","DOI":"10.1038\/s41392-021-00776-0"},{"key":"122","doi-asserted-by":"crossref","unstructured":"Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto MR, Coco B, Cavallone D, Mangia A, Santoro R, Piazzolla V, Lau A, Gaggar A, Subramanian GM, Ferrari C. TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(T)Ide analogues. Gastroenterology. 2018;154(6):1764\u201377.e7.","DOI":"10.1053\/j.gastro.2018.01.030"},{"key":"123","doi-asserted-by":"crossref","unstructured":"Yan Y, Zhao W, Liu W, Li Y, Wang X, Xun J, Davgadorj C. CCL19 enhances CD8(+) T-cell responses and accelerates HBV clearance. J Gastroenterol. 2021;56(8):769\u201385.","DOI":"10.1007\/s00535-021-01799-8"},{"key":"124","doi-asserted-by":"crossref","unstructured":"Heim K, Sagar, Sogukpinar \u00d6, Llewellyn-Lacey S, Price DA, Emmerich F, Kraft ARM, Cornberg M, Kielbassa S, Knolle P, Wohlleber D, Bengsch B, Boettler T, Neumann-Haefelin C, Thimme R, Hofmann M. Attenuated effector T cells are linked to control of chronic HBV infection. Nat Immunol. 2024;25(9):1650\u201362.","DOI":"10.1038\/s41590-024-01928-4"},{"key":"125","doi-asserted-by":"crossref","unstructured":"Venzin V, Beccaria CG, Perucchini C, Delfino P, Bono EB, Giustini L, Moalli F, Grillo M, Fumagalli V, Laura C, Di Lucia P, Reinhard K, Petschenka J, Omokoko TA, Celant A, Ottolini S, Kawashima K, Rav\u00e0 M, De Giovanni M, Inverso D, Kuka M, Kennedy PTF, Guilliams M, Casorati G, Pedica F, Ponzoni M, \u015eahin U, Le Bert N, Bertoletti A, Vascotto F, Guidotti LG, Iannacone M. CD4(+) T cells license Kupffer cells to reverse CD8(+) T cell dysfunction induced by hepatocellular priming. Nat Immunol. 2025;26(8):1352\u201366.","DOI":"10.1038\/s41590-025-02199-3"},{"key":"126","doi-asserted-by":"crossref","unstructured":"Zai W, Yang M, Jiang K, Guan J, Wang H, Hu K, Huang C, Chen J, Fu W, Zhan C, Yuan Z. Optimized RNA interference therapeutics combined with interleukin\u20132 mRNA for treating hepatitis B virus infection. Signal Transduct Target Ther. 2024;9(1):150.","DOI":"10.1038\/s41392-024-01871-8"},{"key":"127","doi-asserted-by":"crossref","unstructured":"Lobaina Y, Hardtke S, Wedemeyer H, Aguilar JC, Schlaphoff V. In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol. 2015;63(2):320\u20137.","DOI":"10.1016\/j.molimm.2014.08.003"},{"key":"128","doi-asserted-by":"crossref","unstructured":"Zhao H, Shao X, Yu Y, Huang L, Amor NP, Guo K, Weng C, Zhao W, Yang A, Hu J, Yang H, Liu Z, Han Q, Shi L, Sun S, Zhang J, Lin A, Yang Y. A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression. NPJ Vaccines. 2024;9(1):22.","DOI":"10.1038\/s41541-024-00813-3"},{"key":"129","doi-asserted-by":"crossref","unstructured":"Ma Z, Cao Q, Xiong Y, Zhang E, Lu M. Interaction between hepatitis B virus and toll-like receptors: Current status and potential therapeutic use for chronic hepatitis B. Vaccines. 2018;6(1):6.","DOI":"10.3390\/vaccines6010006"},{"key":"130","doi-asserted-by":"crossref","unstructured":"Li L, Barry V, Daffis S, Niu C, Huntzicker E, French DM, Mikaelian I, Lanford RE, Delaney WEt, Fletcher SP. Anti-HBV response to toll-like receptor 7 agonist GS\u20139620 is associated with intrahepatic aggregates of T cells and B cells. J Hepatol. 2018;68(5):912\u201321.","DOI":"10.1016\/j.jhep.2017.12.008"},{"key":"131","doi-asserted-by":"crossref","unstructured":"Menne S, Tumas DB, Liu KH, Thampi L, AlDeghaither D, Baldwin BH, Bellezza CA, Cote PJ, Zheng J, Halcomb R, Fosdick A, Fletcher SP, Daffis S, Li L, Yue P, Wolfgang GH, Tennant BC. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS\u20139620 in the Woodchuck model of chronic hepatitis B. J Hepatol. 2015;62(6):1237\u201345.","DOI":"10.1016\/j.jhep.2014.12.026"},{"key":"132","doi-asserted-by":"crossref","unstructured":"Pierson W, Tuefferd M, Herschke F, Slaets L, Crabbe M, Verstappen D, De Pelsmaeker S, Strickland I, Gane EJ, Schwabe C, Zhang Y, Meerts P, Vandenbossche J, Van Remoortere P, Verbrugge I, De Creus A. A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults. Antivir Ther. 2023;28(3):13596535231172878.","DOI":"10.1177\/13596535231172878"},{"key":"133","doi-asserted-by":"crossref","unstructured":"Janssen HL, Lim YS, Kim HJ, Sowah L, Tseng CH, Coffin CS, Elkhashab M, Ahn SH, Nguyen AH, Chen D, Wallin JJ, Fletcher SP, McDonald C, Yang JC, Gaggar A, Brainard DM, Fung S, Kim YJ, Kao JH, Chuang WL, Brooks AE, Dunbar PR. Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection. JHEP Rep. 2024;6(2):100975.","DOI":"10.1016\/j.jhepr.2023.100975"},{"key":"134","doi-asserted-by":"crossref","unstructured":"Ayithan N, Tang L, Tan SK, Chen D, Wallin JJ, Fletcher SP, Kottilil S, Poonia B. Follicular helper T (T(FH)) cell targeting by TLR8 signaling for improving HBsAg-specific B cell response in chronic hepatitis B patients. Front Immunol. 2021;12:735913.","DOI":"10.3389\/fimmu.2021.735913"},{"key":"135","doi-asserted-by":"crossref","unstructured":"Khanam A, Ayithan N, Tang L, Poonia B, Kottilil S. IL-21-deficient T follicular helper cells support B cell responses through IL-27 in patients with chronic hepatitis B. Front Immunol. 2020;11:599648.","DOI":"10.3389\/fimmu.2020.599648"},{"key":"136","doi-asserted-by":"crossref","unstructured":"Salimzadeh L, Le Bert N, Dutertre CA, Gill US, Newell EW, Frey C, Hung M, Novikov N, Fletcher S, Kennedy PT, Bertoletti A. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest. 2018;128(10):4573\u201387.","DOI":"10.1172\/JCI121957"},{"key":"137","doi-asserted-by":"crossref","unstructured":"Lupo KB, Matosevic S. Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy. Cancers. 2019;11(6):769.","DOI":"10.3390\/cancers11060769"},{"key":"138","doi-asserted-by":"crossref","unstructured":"Mizukoshi E, Kaneko S. Immune cell therapy for hepatocellular carcinoma. J Hematol Oncol. 2019;12(1):52.","DOI":"10.1186\/s13045-019-0742-5"},{"key":"139","doi-asserted-by":"crossref","unstructured":"Tang L, Li Q, Chen L, Li X, Gu S, He W, Pan Q, Wang L, Sun J, Yi X, Li Y. IL\u201321 collaborates with anti-TIGIT to restore NK cell function in chronic HBV infection. J Med Virol. 2023;95(10):e29142.","DOI":"10.1002\/jmv.29142"},{"key":"140","doi-asserted-by":"crossref","unstructured":"Pang X, Zhang L, Liu N, Liu B, Chen Z, Li H, Chen M, Peng M, Ren H, Hu P. Combination of pegylated interferon-alpha and nucleos(t)ide analogue treatment enhances the activity of natural killer cells in nucleos(t)ide analogue experienced chronic hepatitis B patients. Clin Exp Immunol. 2020;202(1):80\u201392.","DOI":"10.1111\/cei.13486"},{"key":"141","doi-asserted-by":"crossref","unstructured":"Peppa D, Micco L, Javaid A, Kennedy PT, Schurich A, Dunn C, Pallant C, Ellis G, Khanna P, Dusheiko G, Gilson RJ, Maini MK. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog. 2010;6(12): e1001227.","DOI":"10.1371\/journal.ppat.1001227"},{"key":"142","doi-asserted-by":"crossref","unstructured":"Jin X, Bi J. Prospects for NK-based immunotherapy of chronic HBV infection. Front Immunol. 2022;13:1084109.","DOI":"10.3389\/fimmu.2022.1084109"},{"key":"143","doi-asserted-by":"crossref","unstructured":"Maini MK, Peppa D. NK cells: A double-edged sword in chronic hepatitis B virus infection. Front Immunol. 2013;4:57.","DOI":"10.3389\/fimmu.2013.00057"},{"key":"144","doi-asserted-by":"crossref","unstructured":"Hu Y, Yang A, Li H, Zhao R, Bao C, Yu Y, Wang Y, Wang Z, Zhuo L, Han Q, Zhang Z, Zhang J, Zhao H. Lymph node-targeted STING agonist nanovaccine against chronic HBV infection. Cell Mol Life Sci. 2024;81(1):372.","DOI":"10.1007\/s00018-024-05404-y"},{"key":"145","doi-asserted-by":"crossref","unstructured":"Liu Q, Li J, Zong Q, Duan Z, Liu F, Duan W, Ruan M, Zhang H, Liu Y, Zhou Q, Wang Q. Interferon-induced polarization of M1 macrophages mediates antiviral activity against the hepatitis B virus via the hepcidin-ferroportin axis. Int Immunopharmacol. 2024;134:112219.","DOI":"10.1016\/j.intimp.2024.112219"},{"key":"146","doi-asserted-by":"crossref","unstructured":"Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33(4):547\u201362.","DOI":"10.1016\/j.ccell.2018.03.012"}],"container-title":["Critical Reviews in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/7167e7dd36448e24\/CRI-61090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T20:10:27Z","timestamp":1787083827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/2ff21abf44b19838,74b10211737d60bd,7167e7dd36448e24.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":146,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1615\/critrevimmunol.2026061090","relation":{},"ISSN":["1040-8401"],"issn-type":[{"value":"1040-8401","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}